Caristo Diagnostics Showcases Innovative Cardiac Technology at SCCT
Caristo Diagnostics to Present at SCCT 2025
Caristo Diagnostics, a notable leader in cardiovascular disease diagnostics, is poised to showcase groundbreaking clinical and research results surrounding its CaRi-Heart technology at the upcoming SCCT 2025 conference. The conference offers a platform for medical professionals to engage with cutting-edge innovations in cardiac imaging and risk assessment.
Innovative Predictive Insights from CaRi-Heart Technology
The new findings reveal that the CaRi-Heart FAI-Score technology can accurately predict cardiac risks, even among patients who show low or zero calcium scores—traditionally categorized as low-risk. This advancement not only challenges existing norms but also encourages a re-evaluation of how cardiac risks are assessed in various patient populations.
Significant Research Results Unveiled
Dr. Kenneth Chan, a clinical research fellow from the University of Oxford, will present a pivotal abstract entitled, 'Coronary Inflammation Predicts Cardiac Risk in Patients with No and Moderate Coronary Calcification.' This research is based on an extensive study involving 20,000 patients, illustrating the efficacy of the FAI-Score in identifying risks in those previously deemed safe.
Insights from NHS Implementation
Presentations at the symposium will reflect findings from a large-scale implementation of CaRi-Heart technology at five NHS hospitals in the UK. The results will address how inflammation-driven risk stratification tailors patient management effectively, underscoring the technology’s positive impact on real-world clinical practices.
Engaging Experts at the Caristo Symposium
The Caristo symposium, scheduled for July 19, will feature esteemed experts in cardiology, including Dr. Tim Fairbairn, Dr. Ron Blankstein, and Professor Stefan Neubauer. Their insights will contribute significantly to understanding how CaRi-Heart can influence patient outcomes through innovative data analysis.
Breakthrough Regulatory Approvals
This year marks a significant achievement for Caristo, having attained crucial U.S. regulatory milestones. In February, the FDA granted clearance for the CaRi-Plaque technology, facilitating plaque and stenosis quantification. Subsequently, in March, the AMA CPT Panel approved a new Category III CPT code for the CaRi-Heart technology aimed at detecting coronary inflammation and assessing cardiovascular mortality risk.
Book Your Exclusive Demo and Learn More
Attendees at SCCT can seize the opportunity to book an exclusive demonstration of Caristo’s advanced technologies by arranging an onsite meeting at Booth #304 during the conference. This hands-on experience will allow healthcare professionals to engage directly with the innovations that Caristo presents, enriching their understanding of cardiac risk assessment.
Future Development and Workshops
On July 17, an AI/ML interactive workshop will showcase clinical tools for standardized FAI-Score and plaque analysis, led by noted experts. Following that, on July 18, attendees can look forward to engaging debates regarding the relevance of pericoronary fat analysis in cardiac imaging and other technical advances within the field.
About Caristo Diagnostics
Caristo Diagnostics is revolutionizing heart disease detection through its advanced AI-driven technology, emerging from the University of Oxford. Committed to early detection and personalized prevention, Caristo’s solutions aim to identify hidden risks for heart attacks, paving the way for transformative healthcare solutions. Their innovative efforts are supported by a nexus of leading hospitals and specialists focused on improving cardiovascular outcomes worldwide.
Frequently Asked Questions
What is CaRi-Heart technology?
CaRi-Heart technology measures coronary inflammation to predict cardiac risk, aiding in the identification of heart attack risks before symptoms appear.
When will Caristo present its findings?
Caristo will present its latest findings during the 2025 SCCT annual scientific meeting, scheduled between July 17-20.
Who will be presenting at the symposium?
Dr. Kenneth Chan from the University of Oxford will lead the presentation, alongside other notable cardiology experts.
What are the key regulatory achievements of Caristo in 2025?
This year, Caristo secured FDA clearance for its CaRi-Plaque technology and received a new CPT code approval for CaRi-Heart technology.
How can attendees learn more about Caristo’s technologies?
SCCT attendees can visit Booth #304 for demonstrations and deeper insights into Caristo’s innovations related to cardiac health.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
